What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial
- PMID: 21060068
- DOI: 10.1161/CIRCULATIONAHA.109.905687
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial
Abstract
Background: Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes.
Methods and results: We evaluated 4162 patients enrolled in the PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial (acute coronary syndrome patients randomized to pravastatin 40 mg versus atorvastatin 80 mg). The average follow-up BP (systolic and diastolic) was categorized into 10-mm Hg increments. The primary outcome was a composite of death due to any cause, myocardial infarction, unstable angina requiring rehospitalization, revascularization after 30 days, and stroke. The secondary outcome was a composite of death due to coronary heart disease, nonfatal myocardial infarction, or revascularization. The relationship between BP (systolic or diastolic) followed a J- or U-shaped curve association with primary, secondary, and individual outcomes, with increased events rates at both low and high BP values, both unadjusted and after adjustment for baseline variables, baseline C-reactive protein, and on-treatment average levels of low-density lipoprotein cholesterol. A nonlinear Cox proportional hazards model showed a nadir of 136/85 mm Hg (range 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic) at which the incidence of primary outcome was lowest. The curve was relatively flat for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg.
Conclusions: After acute coronary syndrome, a J- or U-shaped curve association existed between BP and the risk of future cardiovascular events, with lowest event rates in the BP range of approximately 130 to 140 mm Hg systolic and 80 to 90 mm Hg diastolic and a relatively flat curve for systolic pressures of 110 to 130 mm Hg and diastolic pressures of 70 to 90 mm Hg, which suggests that too low of a pressure (especially <110/70 mm Hg) may be dangerous.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00382460.
Similar articles
-
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62. doi: 10.1016/j.jacc.2009.10.005. J Am Coll Cardiol. 2009. PMID: 20082923 Clinical Trial.
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med. 2004 Apr 8;350(15):1495-504. doi: 10.1056/NEJMoa040583. Epub 2004 Mar 8. N Engl J Med. 2004. PMID: 15007110 Clinical Trial.
-
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.J Am Coll Cardiol. 2009 Dec 8;54(24):2290-5. doi: 10.1016/j.jacc.2009.09.010. J Am Coll Cardiol. 2009. PMID: 19958964 Clinical Trial.
-
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].G Ital Cardiol (Rome). 2010 Oct;11(10 Suppl 1):78S-83S. G Ital Cardiol (Rome). 2010. PMID: 21416832 Review. Italian.
-
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?Can J Cardiol. 2005 Jan;21(1):85-90. Can J Cardiol. 2005. PMID: 15685308 Review.
Cited by
-
Association of Pre-PCI Blood Pressure and No-Reflow in Patients with Acute ST-Elevation Coronary Infarction.Glob Heart. 2024 Mar 4;19(1):28. doi: 10.5334/gh.1309. eCollection 2024. Glob Heart. 2024. PMID: 38464557 Free PMC article.
-
Central arterial pressure predicts in-hospital major adverse cardiovascular events after acute ST-segment elevation myocardial infarction: a retrospective cohort study.Ann Transl Med. 2023 Mar 15;11(5):214. doi: 10.21037/atm-23-1079. Ann Transl Med. 2023. PMID: 37007547 Free PMC article.
-
Influence of baseline arterial stiffness on effects of intensive compared with standard blood pressure control: a post hoc analysis of the STEP trial.BMC Med. 2022 Oct 20;20(1):358. doi: 10.1186/s12916-022-02556-1. BMC Med. 2022. PMID: 36261812 Free PMC article. Clinical Trial.
-
Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores.Nutrients. 2022 Jul 30;14(15):3163. doi: 10.3390/nu14153163. Nutrients. 2022. PMID: 35956339 Free PMC article.
-
Impact of multivessel versus single-vessel disease on the association between low diastolic blood pressure and mortality after acute myocardial infarction with revascularization.Cardiol J. 2024;31(1):72-83. doi: 10.5603/CJ.a2022.0067. Epub 2022 Jul 12. Cardiol J. 2024. PMID: 35818795 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
